Thermo Fisher Scientific

AMFMSTUDIOS is the proud creator of the Fisher Thermo Scientific TaqPath COVID-19 High-Throughput Combo Kit Amplitude Marketing Videos, created, edited and produced by Christopher Thompson.  Thermo Fisher Scientific now provides half the Covid-19 tests world-wide.


 “We had a leadership meeting today and our amplitude marketing was called out as the new benchmark for all clinical marketing for Thermo Fisher. They said it looks like we’re delivering a high end clinical grade solution the likes of which Thermo has not seen before. And lots of that is because of your hard work – so thank you.”


FDA Authorizes New High-Throughput, Automated System for Leading COVID-19 Test

Apr. 12, 2021

The Amplitude Solution with the TaqPath COVID-19 High-Throughput Combo Kit enables laboratories to rapidly scale high-sensitivity PCR testing capacity as schools and employers seek increased testing to support reopening strategies

WALTHAM, Mass., April 12, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the Thermo Fisher Scientific Amplitude Solution with the TaqPath COVID-19 High-Throughput Combo Kit.

FDA Authorizes New High-Throughput, Automated System for Leading COVID-19 Test


Amplitude Solution with TaqPath COVID-19 High-Throughput Combo Kit enables labs to scale high-sensitivity PCR testing

The Amplitude Solution enables clinical and public health laboratories to scale gold standard PCR testing and process up to 8,000 samples in a single day with minimal staffing resources and a secured supply of kits, reagents and consumables to meet their testing needs. The Amplitude Solution has been implemented globally including labs in Europe and Japan.

“While COVID-19 cases globally may be decreasing in some areas as vaccines become more widely available, there continues to be a demand for frequent routine testing to control future outbreaks,” said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. “For population-wide testing programs, lab-based PCR is the best fitting technology, providing confidence in results, capacity to process thousands of samples a day, and consistent, reliable turnaround times. The Amplitude Solution can help support a systematic testing strategy by enabling labs to quickly scale their testing and begin processing high-volume samples, even with limited personnel.”

The Amplitude Solution is a molecular diagnostic testing system that helps clinical labs expand testing capacity by combining Thermo Fisher’s extraction and real-time PCR instruments with liquid handling products from Tecan Group. The modular system utilizes a high-throughput version of Thermo Fisher’s Applied Biosystems TaqPath COVID-19 Combo Kit, which received EUA in March 2020, to process samples in four steps with minimal hands-on time and laboratory space requirements. The kit’s multi-gene target design and updated interpretive software may help labs detect SARS-CoV-2 variants.

For more information on the Amplitude Solution, please visit